Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Jul 1.

Published in final edited form as: Immunogenetics. 2012 Feb 24;64(7):507–523. doi: 10.1007/s00251-012-0606-4

Fig. 1 — Stimulation of CD4⁺ T-cell lines from A. marginale OM-immunized cattle with synthetic peptides from VirB9-1, VirB9-2, and VirB10. Short term T-cell lines from six animals (animal number and RFLP type in parenthesis is indicated on the top of each panel) were stimulated with 10 or 20 μg/ml of peptides from (a) VirB9-1 peptides P1-P13, (b) VirB9-2 peptides P1-P14, and (c) VirB10 peptides P1, P2.1, P2.2, and P3-P22. As a negative control, a 30-mer peptide derived from B. bovis Rap1 was used at an equal concentration. Additional controls were A. marginale OM and the full length recombinant protein used at 1 μg/ml. Results are presented as SI, and responses significantly higher than those for B. bovis Rap1 P1 are indicated with asterisks, where P <0.05

Fig. 1 — Stimulation of CD4⁺ T-cell lines from A. marginale OM-immunized cattle with synthetic peptides from VirB9-1, VirB9-2, and VirB10. Short term T-cell lines from six animals (animal number and RFLP type in parenthesis is indicated on the top of each panel) were stimulated with 10 or 20 μg/ml of peptides from (a) VirB9-1 peptides P1-P13, (b) VirB9-2 peptides P1-P14, and (c) VirB10 peptides P1, P2.1, P2.2, and P3-P22. As a negative control, a 30-mer peptide derived from B. bovis Rap1 was used at an equal concentration. Additional controls were A. marginale OM and the full length recombinant protein used at 1 μg/ml. Results are presented as SI, and responses significantly higher than those for B. bovis Rap1 P1 are indicated with asterisks, where P <0.05